Clarus Therapeutics Holdings, Inc. (CRXT)
| Previous close | 0.3864 |
| Open | 0.3800 |
| Bid | 0.3720 x 2900 |
| Ask | 0.3732 x 800 |
| Day's range | 0.3500 - 0.3900 |
| 52-week range | 0.3500 - 31.2400 |
| Volume | |
| Avg. volume | 13,549,685 |
| Market cap | 19.477M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.8000 |
| Earnings date | 16 May 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.25 |
- GlobeNewswire
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to eight NORTHBROOK, Ill., May 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical ne
- GlobeNewswire
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., May 16, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women,
- GlobeNewswire
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The d
